Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

6.330 +0.180 (+2.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
The Latest Analyst Ratings for Rocket Pharmaceuticals
Via Benzinga
Where Rocket Pharmaceuticals Stands With Analysts
Via Benzinga
Expert Ratings for Rocket Pharmaceuticals
Via Benzinga
SVB Leerink Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know
Via Benzinga
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
Nasdaq Down Over 3%; IsoPlexis Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 600 points on Thursday. 
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Dow Tumbles 300 Points; US Economy Expands 3.2% In Q3
U.S. stocks traded lower this morning, with the Dow Jones dropping over 300 points on Thursday. 
Via Benzinga
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Completes Acquisition of Renovacor
From Rocket Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why DraftKings Shares Are Trading Lower By 5%; Here Are 24 Stocks Moving Premarket
Gainers Talkspace, Inc. (NASDAQ: TALK) shares rose 48.3% to $0.89 in pre-market trading. Talkspace recently named Jon Cohen as CEO. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! It's time to check out the biggest pre-market stock movers that traders will want to know about on Monday! 
Via InvestorPlace
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
This Stock Is Up 106% In 2022 And Analysts Love It, But Jim Cramer Says 'There's Too Much Political Risk'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies." 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
From Rocket Pharmaceuticals, Inc.
Via Business Wire
$20 Million Bet On Rocket Pharmaceuticals? 3 Stocks Insiders Are Buying
Although US crude oil prices traded lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
From Rocket Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.